Head to Head Analysis: LENSAR (NASDAQ:LNSR) versus enVVeno Medical (NASDAQ:NVNO)

LENSAR (NASDAQ:LNSR) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Volatility & Risk

LENSAR has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Profitability

This table compares LENSAR and enVVeno Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENSAR	-87.12%	N/A	-73.64%
enVVeno Medical	N/A	-61.45%	-56.88%

Insider and Institutional Ownership

40.2% of LENSAR shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 66.0% of LENSAR shares are held by company insiders. Comparatively, 15.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for LENSAR and enVVeno Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1	2	0	0	1.67
enVVeno Medical	1	1	0	0	1.50

LENSAR currently has a consensus price target of $15.00, suggesting a potential upside of 24.17%. Given LENSAR’s stronger consensus rating and higher probable upside, research analysts plainly believe LENSAR is more favorable than enVVeno Medical.

Valuation and Earnings

This table compares LENSAR and enVVeno Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$53.49 million	2.70	-$31.40 million	($4.39)	-2.75
enVVeno Medical	N/A	N/A	-$21.82 million	($37.89)	-0.28

enVVeno Medical has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Summary

LENSAR beats enVVeno Medical on 7 of the 12 factors compared between the two stocks.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.